Biogen gains prominent ally in bid for Supreme Court to review Tecfidera patent case

After the U.S. Court of Appeals for the Federal Circuit scuttled Biogen’s bid for a rehearing on its Tecfidera patent case in March, the big biotech was left with few options but to appeal to the Supreme Court. Now, as the high court considers whether to take up the case, Biogen has snared the support of a prominent science and legal advocacy group.